SCD-HeFT
Sudden Cardiac Death in Heart Failure Trial
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 2,521 patients with heart failure (NYHA II–III, EF ≤ 35 %), an implantable defibrillator reduced all-cause mortality compared with placebo or amiodarone.
N
2.521
Design
RCT, double-blind drug arms
Endpunkt
All-cause mortality
Relevanz
1
ErgebnisICD HR 0.77; amiodarone no better than placebo.
Bardy GH, et al. N Engl J Med. 2005;352(3):225-237. 10.1056/NEJMoa043399
Diskussion & Kritik
Extended ICD benefit to non-ischaemic HF and showed amiodarone is not prognostically useful. The benefit was concentrated in NYHA class II.